A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
PHASE2
The study was a Phase II, randomized, placebo-controlled, double-blind, mul...
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
PHASE2
This was a randomized, placebo-controlled, double-blind study of vismodegib...
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
PHASE1
This multicenter, randomized, double-blind, placebo-controlled study will e...